Purchase Order 75N91020P00889

Award Date 9/9/20
Potential Completion Date 9/8/21
Potential Value $81K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Netherlands
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), awarded a $6,560 firm-fixed-price purchase order to Pepscan Presto B.V., a foreign-owned, for-profit organization, for custom peptide synthesis services. The award, which had a performance period ending on September 30, 2015, was not set aside for any specific business category. Pepscan Presto B.V. is a premier provider of peptide-based products and services with...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), awarded a $7,900.00 Firm Fixed Price purchase order contract to Pepscan Presto B.V., a foreign-owned for-profit organization, for the provision of PEPCHIPTM KINOMICS SLIDES. This contract, with a performance period ending on September 30, 2015, did not have a set-aside designation. Pepscan Presto B.V. is an experienced provider of peptide-based products and services,...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $132,000 firm fixed price purchase order to JPT Peptide Technologies GMBH. The contract calls for JPT to design, synthesize, purify, analyze, pool, and test overlapping peptides of the rabies envelope glycoprotein and HPV16 capsid L1 protein. These peptides will be used by NCI's Laboratory of Cellular Oncology to evaluate the potential of viral peptide libraries for cancer treatment. Key...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to JPT Peptide Technologies GMBH, a foreign-owned for-profit manufacturer of custom peptides and related research products. The $3,620 firm fixed price purchase order is for the delivery of peptide microarrays displaying peptides from a previous order, in support of NIAID's research activities. The award has no set-aside...
This is a $12,621.25 firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Pepperprint GmbH, a biotech company in Heidelberg, Germany. The contract is for the custom generation of peptides to support NIAID's research efforts. Pepperprint has previously received federal contracts from the U.S. Department of Agriculture and HHS/FDA for similar peptide microarray...
The National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $5,222.30 firm fixed price purchase order contract to JPT Peptide Technologies GmbH, a foreign-owned for-profit manufacturer of custom peptides and peptide-based products. The contract supports research related to cancer, COVID-19, allergies, and infectious diseases through the provision of peptide mixtures, reagents, assay kits, laboratory testing services, drugs and biologicals....
This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services (HHS), to Genscript USA Inc., a for-profit biotechnology company based in Piscataway, New Jersey. The $3,464.90 contract is for peptide services and was awarded on September 8, 2015 with a completion date of September 9, 2015. The award does not have a set-aside designation. Genscript has received numerous prime and subcontracts from...
This federal contract award was issued by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to JPT Peptide Technologies GMBH, a foreign-owned for-profit manufacturer of custom peptides and peptide-based products. The $4,652 firm fixed price purchase order supports the provision of peptide mixtures, reagents, assay kits, and testing services related to cancer, COVID-19, allergies, and infectious disease research. JPT has received over $250,000...
This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services (HHS), to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract, valued at $8,872.00, is for "PEPTIDE SERVICES/GENSCRIPT/GAL CAFRI" and does not have a set-aside designation. Genscript, a for-profit organization, has a long history of providing a wide range of molecular biology products and...
This is a firm fixed price purchase order contract awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to JPT Peptide Technologies GmbH, a foreign-owned for-profit manufacturer of custom peptides and related products. The contract, valued at $5,497.50, is for the delivery of 40 aliquots of a Marburg glycoprotein-Musoke peptide mixture. The contract supports research related to infectious diseases and does not have a set-aside...

This is a $81,460 firm fixed price purchase order awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS), to Pepscan Presto B.V., a foreign-owned for-profit company. The contract is for the acquisition, characterization, and optimization of constrained peptides targeting glypican, in support of the NCI's Molecular Imaging Program. The work will involve creating peptide libraries, synthesizing and validating lead peptide candidates, and shipping the top 15 candidates to the NCI. This was a competitive solicitation with no set-aside designation, and was awarded on September 9, 2020 with a 12-month period of performance. Pepscan Presto has previously received awards from other HHS agencies, including the National Institute of Allergy and Infectious Diseases and the Department of the Navy, for peptide synthesis and related services.

Generated 4/1/25, 5:35 PM